Home
overview
This key event will take a look at how Pharma and Biotech can work together and how Biotech can form alliances with other Biotech, to minimise their problem areas and maximise their assets, ultimately resulting in healthier profits for both partners. Such alliances are becoming critical to drug development, however what makes for a successful partnership remains poorly understood. The conference will include specific case studies and experiences of how successful partnerships and alliances have been established and conversely, of what can be learnt from less successful attempts at collaboration. The event will look at how best to market yourself to potential partners, how to ensure each partner’s enthusiasm is initiated and maintained, how to devise an appropriate contract and how to carry through the practicalities of a partnership agreement.

A unique opportunity to learn from leading industry experts including:
Dr Ian Kirk, Discovery Alliances Manager, AstraZeneca
Dr William Harrison, Head, Global Search & Evaluation Europe, Business Development & Licensing, Novartis
Prof Ray Hill, Executive Director, Licensing & External Research, Europe, Merck
Dr Peter Johann, Head, Corporate Division, Corporate Development, Boehringer Ingelheim
Dr Wolfgang Schmidt, Scientific Affairs, Aventis
Dr Stefan Fischer, Global Alliance Director, Hoffman-La Roche
Joshua Kalkstein, Assistant General Counsel, Pfizer
Rimma Sandler Bradley, Worldwide Alliances, Licensing & Acquisitions, Procter & Gamble
Mehernosh Lentin, European Supply Chain Director, Baxter
Onno van de Stolpe, Chief Executive Officer, Galapagos Genomics
Dr Bart Wuurman, Director, Business Development, Antisoma

Benefits of attending:
COLLABORATIONS: explore the opportunities that arise from working together with other pharma or biotech companies
PARTNERSHIPS: find out how to create lasting relationships
EFFECTIVE DEAL-MAKING: learn about the benefits derived from due diligence
LICENSING: discover the key success factors in optimising a drugs commercial potential
MERGERS AND ACQUISITIONS: find out how M & A can accelerate corporate development
THE MARKET, THE COMPETITION: comparing collaborations in Europe and America

Also:
INTERACTIVE DISCUSSION – Managing Partnerships: an opportunity to discuss the key issues with industry experts on the panel

“Given the list of confirmed speakers and the topics, I am convinced that this event is going to be successful and fruitful for all participants”
Dr Roland Mohr, Head, Site Operations, Aventis

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Michael Stone

Michael Stone, Of Counsel, Covington & Burling

9:10 MANAGING PARTNERSHIPS

Dr Ian Kirk

Dr Ian Kirk, Discovery Alliances Manager, AstraZeneca

  • Choosing the right partner
  • Building support for both parties
  • Managing conflicts
  • Continuous improvement
  • Reaching and measuring goals
  • 9:40 SETTING EXPECTATIONS

    Dr Jim Phillips

    Dr Jim Phillips, Managing Director, Diabetology

  • The importance of understanding each sides needs
  • Helping your partner to see your view
  • Hard and soft aspects of negotiation
  • Explanatory vs exploratory tactics
  • 10:20 MANAGING ALLIANCE CAPABILITY AND SUCCESS

    Charles E. Macfarlance

    Charles E. Macfarlance, Executive Director, Worldwide Alliances, Licensing & Acquisitions, Proctor & Gamble

  • Alliances beyond contracts
  • Building alliance management capabilities
  • Alignment between the two companies
  • 11:00 Morning Coffee

    11:20 NOVARTIS GLOBAL SEARCH & EVALUATION

    Dr William Harrison

    Dr William Harrison, Head, Global Search & Evaluation Europe, Business Development & Licensing, Novartis

    12:00 BIOLOGICAL ADVANCES

    Dr Ray Hill

    Dr Ray Hill, Executive Director, Licensing & External Research, Europe, Merck

  • Where are the key biological discoveries being made?
  • How does big pharma ensure access to the best drug discovery targets?
  • Can biotech exploit its discoveries without the aid of big pharma?
  • Exploiting synergies between large and small companies to the benefit of both
  • 12:40 Networking Lunch

    13:40 LESSONS LEARNT FROM BIOTECH AND BIOTECH COLLABORATIONS

    Dr Stefan Fischer

    Dr Stefan Fischer, Global Alliance Director, Hoffman-La Roche

  • Structural aspects of pharma and biotech
  • Comparing collaborations in Europe and America
  • The market, the competition
  • What does the future hold for big pharma?
  • 14:20 PARTNERING WITH PHARMA

    Onno van de Stolpe

    Onno van de Stolpe, Chief Executive Officer, Galapagos Genomics

  • Rational for partnerships in a hybrid biotech business model
  • Advantages of partnerships for directing the strategic research choices
  • Impact of partnerships on the biotech cashflow and the confidence of its investors
  • The SilenceSelect partnership offering as case study
  • 15:00 THE PHARMA LICENCING MARKET

    Dr Sian Renfrey

    Dr Sian Renfrey, Senior Consultant, Wood Mackenzie

    15:40 Afternoon Tea

    16:00 THE ROCHE – ANTISOMA ALLIANCE

    Dr Bart Wuurman

    Dr Bart Wuurman, Director, Business Development, Antisoma

  • Goals of the collaboration
  • Collaboration structure
  • Strategic implications
  • Practical implications for Antisoma
  • 16:40 PANEL DISCUSSION: MANAGING PARTNERSHIPS

    Michael Stone

    Michael Stone, Of Counsel, Covington & Burling

    Dr Ian Kirk

    Dr Ian Kirk, Discovery Alliances Manager, AstraZeneca

    Onno van de Stolpe

    Onno van de Stolpe, Chief Executive Officer, Galapagos Genomics

    Dr Ray Hill

    Dr Ray Hill, Executive Director, Licensing & External Research, Europe, Merck

    Rod Richards

    Rod Richards, Chief Executive Officer, Microscience

    17:20 Chairman's Closing Remarks and Close of Day One
    Followed by SMi's Networking Drinks Reception

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Paul Haycock

    Dr Paul Haycock, Director, Apax Partners

    9:10 COLLABORATIONS IN COMBINATION THERAPIES

    Larry Stambaugh

    Larry Stambaugh, Chairman, President & Chief Executive Officer, Maxim Pharmaceuticals

  • Working with competing partners
  • Timing of collaborations and marketing agreements
  • Late stage opportunities
  • In-licensing of technologies vs corporate acquisition
  • Risks/rewards associated with acquisition vs in-licensing
  • 9:40 BUILDING A SUCCESSFUL BIOTECH COMPANY

    Dr Paul Haycock

    Dr Paul Haycock, Director, Apax Partners

  • Management, management, management
  • Seed to start-up
  • The £1-5m gap
  • Serious VC financing
  • Where is everyone’s exit?
  • 10:20 MORE EFFECTIVE DEAL MAKING

    Dr Nigel Whittle

    Dr Nigel Whittle, Principal Consultant, PA Consulting

  • Drivers from collaboration and types of deals
  • Why many consolidating deals fail to deliver the promised value
  • How to improve the probability that deals will deliver
  • The importance of rigorous and independent due diligence
  • Best practice in due diligence
  • The importance of following through with full implementation
  • 11:00 Morning Coffee

    11:20 INTELLECTUAL PROPERTY ISSUES IN PARTNERING

    David Harper

    David Harper, Partner, McDonnell, Boehnen, Hulbert & Berghoff

  • Intellectual property due diligence
  • Key intellectual property issues in negotiating partnerships
  • Case law considerations
  • Strategies to maximise protection
  • 12:00 MANAGING MULTIPLE PARTNERSHIPS

    Dr Adrian Carter

    Dr Adrian Carter, CD Corporate Development, Boehringer Ingelheim

  • Partnering is an essential element of future growth
  • Licensors intend to keep development and marketing rights requiring collaboration structures
  • Dedicated structures to address complexity
  • Experience with governance structures
  • 12:40 Networking Lunch

    13:30 Chairman's Opening Remarks - Afternoon Session

    Joshua Kalkstein

    Joshua Kalkstein, Assistant General Counsel, Pfizer

    13:40 PATENT LAW RESEARCH EXEMPTION

    Joshua Kalkstein

    Joshua Kalkstein, Assistant General Counsel, Pfizer

  • State of the law in the UK and Japan
  • Hatch-Waxman Act and Roche vs Bolar
  • Madey vs Duke
  • Bristol-Myers Squibb vs Rhone Poulenc
  • Bayh-Dole Act and 1999 NIH Guidelines
  • The way to the future?
  • 14:20 USING M & A AS A MEANS TO ACCELERATE CORPORATE DEVELOPMENT

    Dr Enda Gribbon

    Dr Enda Gribbon, , Celltech Group

  • Goals for M & A activity · Transformation of the business model · Expanding geographic footprint · Augmenting technology platforms · Augmenting product pipeline
  • Strategic considerations
  • M & A in tandem with licensing and partnership models
  • 15:00 COMPETITIVE INTELLIGENCE

    Richard Withers

    Richard Withers, Managing Director, Europe, Fuld & Co.

  • What competitive intelligence is and what it is not!
  • Competitive intelligence in the pharmaceutical industry · Why is it used? · When is it used? · How is it used?
  • Competitive intelligence used specifically in collaborations and partnerships
  • 15:40 Afternoon Tea

    16:00 INTEGRATED LICENSING

    Kevin Quinn

    Kevin Quinn, Manager, Business Planning & Information, Helsinn Healthcare

  • Definition of ‘integrated licensing’
  • What are a development company’s strategic considerations for the commercial optimisation of its pipeline?
  • How can integrated licensing company help a development company realise the full commercial potential of its pipeline portfolio?
  • Case studies demonstrating the successful development of ‘unselected’ drug candidates
  • Key success factors for win-win partnerships with integrated licensing companies
  • 16:40 MANAGING CONTINGENCY PLANNING WITH ARMED SERVICES

    Mehernosh Lentin

    Mehernosh Lentin, European Supply Chain Director, Baxter

  • Current process of procurement and disposal is expensive
  • Expensive and lack of reactivity is the end result
  • How to develop an operating model
  • Funding the process model
  • Setting the deal
  • Establishing the on-going relationship
  • 17:20 Chairman’s Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.